Navigation Links
NBTY Closes on Purchase of Leiner Health Products
Date:7/14/2008

RONKONKOMA, N.Y., July 14 /PRNewswire-FirstCall/ -- NBTY, Inc. (NYSE: NTY) (http://www.NBTY.com), a leading global manufacturer and marketer of nutritional supplements, today announced that it has completed the purchase of substantially all of the assets of Leiner Health Products Inc. for approximately $371 million. The terms of the Asset Purchase Agreement provide for various working capital adjustments.

NBTY is acquiring substantially all of Leiner's assets, including its U.S. store brand vitamins, minerals and supplements products as well as Vita Health Products, Inc., Leiner's Canadian subsidiary.

Moelis & Company LLC provided advisory services and Farrell Fritz, P.C. provided legal advice in connection with the acquisition.

NBTY Chairman and CEO, Scott Rudolph, said: "The Leiner acquisition will further enhance our manufacturing capabilities and dominant market presence as the worldwide leader in the nutritional supplement industry. NBTY's history of successful strategic acquisitions reflects our commitment to generating growth, providing the highest quality service to our customers and increasing shareholder value."

About Leiner Health Products

Founded in 1973 and headquartered in Carson, California, Leiner Health Products is America's leading manufacturer of store brand vitamins, minerals, and nutritional supplements and supplies the food, drug, mass merchant and warehouse club retail market. Leiner provides leading retailers with over 2,000 products to help its customers create and market high-quality store brands at low prices. It is also the largest supplier to the U.S. military and markets its own brand of vitamins under YourLife(R).

ABOUT NBTY

NBTY is a leading global vertically integrated manufacturer, marketer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world. Under a number of NBTY and third party brands, the Company offers over 22,000 products, including products marketed by the Company's Nature's Bounty(R) (http://www.NaturesBounty.com), Vitamin World(R) (http://www.VitaminWorld.com), Puritan's Pride(R) (http://www.Puritan.com), Holland & Barrett(R) (http://www.HollandAndBarrett.com), Rexall(R) (http://www.Rexall.com), Sundown(R) (http://www.SundownNutrition.com), MET-Rx(R) (http://www.MetRX.com), Worldwide Sport Nutrition(R) (http://www.SportNutrition.com), American Health(R) (http://www.AmericanHealthUS.com), GNC (UK)(R) (http://www.GNC.co.uk), DeTuinen(R) (http://www.DeTuinen.nl), LeNaturiste(TM) (http://www.LeNaturiste.com), SISU(R) (http://www.SISU.com), Solgar(R) (http://www.Solgar.com), Good 'n' Natural(R) (http://www.goodnnatural.com), Home Health(TM) (http://www.homehealthus.com) and Ester-C(R) (http://www.Ester-C.com) brands.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terminology such as "subject to," "believe," "expects," "plan," "project," "estimate," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. Although all of these forward looking statements are believed to be reasonable, they are inherently uncertain. Factors which may materially affect such forward-looking statements include: (i) slow or negative growth in the nutritional supplement industry; (ii) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio- terrorism, civil unrest or disruption of mail service; (iii) adverse publicity regarding nutritional supplements; (iv) inability to retain customers of companies (or mailing lists) recently acquired; (v) increased competition; (vi) increased costs; (vii) loss or retirement of key members of management; (viii) increases in the cost of borrowings and/or unavailability of additional debt or equity capital; (ix) unavailability of, or inability to consummate, advantageous acquisitions in the future, including those that may be subject to bankruptcy approval or the inability of NBTY to integrate acquisitions into the mainstream of its business; (x) changes in general worldwide economic and political conditions in the markets in which NBTY may compete from time to time; (xi) the inability of NBTY to gain and/or hold market share of its wholesale and/or retail customers anywhere in the world; (xii) unavailability of electricity in certain geographical areas; (xiii) the inability of NBTY to obtain and/or renew insurance and/or the costs of the same; (xiv) exposure to and expense of defending and resolving product liability and intellectual property claims and other litigation; (xv) the ability of NBTY to successfully implement its business strategy; (xvi) the inability of NBTY to manage its retail, wholesale, manufacturing and other operations efficiently; (xvii) consumer acceptance of NBTY's products; (xviii) the inability of NBTY to renew leases for its retail locations; (xix) the inability of NBTY's retail stores to attain or maintain profitability; (xx) the absence of clinical trials for many of NBTY's products; (xxi) sales and earnings volatility and/or trends for the Company and its market segments; (xxii) the efficacy of NBTY's Internet and on-line sales and marketing strategies; (xxiii) fluctuations in foreign currencies, including the British pound, the Euro and the Canadian dollar; (xxiv) import-export controls on sales to foreign countries; (xxv) the inability of NBTY to secure favorable new sites for, and delays in opening, new retail and manufacturing locations; (xxvi) introduction of and compliance with new federal, state, local or foreign legislation or regulation or adverse determinations by regulators anywhere in the world (including the banning of products) and more particularly Good Manufacturing Practices in the United States, the Food Supplements Directive and Traditional Herbal Medicinal Products Directive in Europe and Section 404 requirements of the Sarbanes- Oxley Act of 2002; (xxvii) the mix of NBTY's products and the profit margins thereon; (xxviii) the availability and pricing of raw materials; (xxix) risk factors discussed in NBTY's filings with the U.S. Securities and Exchange Commission; (xxx) adverse effects on NBTY as a result of increased energy prices and potentially reduced traffic flow to NBTY's retail locations; (xxxi) adverse tax determinations; (xxxii) the loss of a significant customer of the Company; (xxxiii) potential investment losses as a result of liquidity conditions; and (xxxiv) other factors beyond the Company's control.

Readers are cautioned not to place undue reliance on forward-looking statements. NBTY cannot guarantee future results, trends, events, levels of activity, performance or achievements. NBTY does not undertake and specifically declines any obligation to update, republish or revise forward- looking statements to reflect events or circumstances after the date hereof or to reflect the occurrences of unanticipated events.

Consequently, such forward-looking statements should be regarded solely as NBTY's current plans, estimates and beliefs.

Contact: Harvey Kamil Carl Hymans

NBTY, Inc. G.S. Schwartz & Co.

President & Chief Financial Officer 212-725-4500

631-200-2020 carlh@schwartz.com

carlhymans@gmail.com


'/>"/>
SOURCE NBTY, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Retired Respironics Chairman Jerry McGinnis and Renal Solutions CEO Pete DeComo Join ALung Technologies Board of Directors; ALung Closes on $1 Million Bridge Financing
2. Oaks Development Group Closes on Second San Antonio Project
3. Memory Pharmaceuticals Closes Second Tranche of Equity Financing with The Stanley Medical Research Institute
4. American Scientific Resources, Inc. Discloses Reviewed Financials
5. Sprinters closest to starter pistol have advantage over those farther away, says study
6. Angioslide Closes US$8.6million Series C Financing
7. 2008 Bank of America Chicago Marathon Registration Closes as Race Reaches 45,000 Participant Capacity
8. Health Plan One Closes $6.5 Million Series A Financing
9. MM2 Group Closes Sale for New Venture in China
10. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
11. China Sky One Medical, Inc. Closes Acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Angeles, CA (PRWEB) , ... February 10, 2016 ... ... Programming (NLP) practitioner, is known locally for a series of therapeutic sessions to ... in-the-moment in their characters and in their lives. The series, known as “Mindfulness ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... master charity program created to assist the local community. Pledging to select a ... and nonprofit organizations in the area. Their goal is to bring community awareness ...
(Date:2/10/2016)... ... ... Ongoing news of the ravages of traumatic brain injury (TBI) among former ... takes a closer look at cases of TBI being managed by their members. The ... the aging population, and identifies the challenges associated with their care. , During the ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed a ... network of laboratory service centers across the country. Launched in April of 2015, Apifiny ... detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... cell disease and heart failure, today announced the pricing ... a price to the public of $0.275 per unit. ... common stock and one warrant to purchase one share ... of $0.42 per share. The warrants are exercisable six ...
(Date:2/10/2016)... Feb. 10, 2016  Silicon Biosystems Menarini Inc., ... that help uncover the biological complexities of disease ... a developer of innovative technologies for genomics research, ... aimed at enabling translational researchers to obtain high-quality ... hundred tumor and normal cells in an optimized ...
(Date:2/10/2016)... Feb. 9, 2016 CTI BioPharma Corp. ... an update regarding the clinical studies being conducted ... for pacritinib. Following the issuance of the Company,s ... clinical hold issued by the U.S. Food and ... Company received an oral communication from the FDA ...
Breaking Medicine Technology: